The effect of 12 weeks carnosine supplementation on renal functional integrity and oxidative stress in pediatric patients with diabetic nephropathy: a randomized placebo-controlled trial
Randomised controlled trialHumansWith ACE inhibitor (both groups, background therapy)
This study tested carnosine together with ACE inhibitor (both groups, background therapy). Its results cannot be assigned to carnosine alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 90 children with type 1 diabetes and nephropathy (45 carnosine, 45 placebo)
- Dose used in the study
- 1 g carnosine per day
- Duration
- 12 weeks
- What was measured
- HbA1c, urinary albumin excretion, alpha-1-microglobulin (tubular damage marker), total antioxidant capacity and malondialdehyde.
What the authors reported
In the carnosine group, HbA1c fell from 8.2% to 7.4%, urinary albumin excretion from 91.7 to 38.5 mg/g creatinine, alpha-1-microglobulin from 16.5 to 9.3 mg/L and malondialdehyde from 25.5 to 18.2 nmol/mL over 12 weeks. Total antioxidant capacity rose compared with baseline and with placebo (p < 0.001). No adverse reactions were reported. The authors concluded carnosine improved oxidative stress, glycaemic control and renal function.
Limits of this study
Conducted in Egypt. Twelve weeks. Children with type 1 diabetes already on ACE inhibitors, so results may not apply to adults or type 2 diabetes. The abstract gives before-and-after values for the carnosine group and a placebo comparison only for total antioxidant capacity. Full text not read.
Source
PubMed 28744992 · doi:10.1111/pedi.12564
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.